Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700227 · ClinicalTrials.gov registry record · NA
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer
A NA study, sponsored by Varian, a Siemens Healthineers Company.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT05700227: Clinical Trial NA study, sponsored by Varian, a Siemens Healthineers Company.
NCT05700227 is a NA study that was terminated before completion, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05700227, a NA study, was terminated before completion, sponsored by Varian, a Siemens Healthineers Company.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxicity compared with the historically reported rate for non-adaptive radiation therapy. The Common Terminology Criteria for Adverse Events (CTCAE) version 5 assessment tool will be utilized.
Primary Outcome
Acute gastrointestinal and genitourinary CTCAE v5 grade 3 or higher toxicity
Interventions
- RADIATION Daily Adaptive External Beam Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2024-05-09 |
| Phase | NA |
Why NCT05700227 stopped before completion
NCT05700227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Daily Adaptive External Beam Radiation Therapy is the first listed.
NCT05700227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05700227 about?
NCT05700227 is a clinical study titled "Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer". This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxic...
What is the current status of trial NCT05700227?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2023-02-02. Estimated completion is 2024-05-09.
What interventions are being tested in trial NCT05700227?
The interventions under investigation include: Daily Adaptive External Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05700227?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05700227's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI